PARIS (dpa-AFX) - Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi (SNYNF, SNY) announced two placebo-controlled Phase 3 studies evaluating investigational dupilumab in adult patients with inadequately controlled moderate-to-severe atopic dermatitis met their primary endpoints. In the studies, treatment with dupilumab as monotherapy significantly improved measures of overall disease severity, skin clearing, itching, quality of life, and mental health.
The LIBERTY AD Phase 3 clinical program consists of five trials of patients. FDA granted dupilumab Breakthrough Therapy designation in atopic dermatitis in November 2014.
Copyright RTT News/dpa-AFX